Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Focal Segmental Glomerulosclerosis: early-phase trial registry
13 of 20 indexed Focal Segmental Glomerulosclerosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 13 currently recruiting · #848 of 28,707 conditions by registered trial count
Focal Segmental Glomerulosclerosis: 20 US clinical trials tracked, 13 recruiting.
Focal Segmental Glomerulosclerosis is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Travere Therapeutics, running 4 of these trials.
Enrollment posture brief
Registry condition focal-segmental-glomerulosclerosis
OPEN 13 | RECR 65% | LATE 3 | EARLY 8 | RANK #848 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Metastatic Triple-Negative Breast Carcinoma (65% recruiting · 20 trials)
Focal Segmental Glomerulosclerosis lists 13 open slots (65% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Focal Segmental Glomerulosclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Focal Segmental Glomerulosclerosis is recruiting above its size-band peers.
13 of 20 indexed trials (65%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Focal Segmental Glomerulosclerosis research.
Travere Therapeutics accounts for 4 of 20 trials (20%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Focal Segmental Glomerulosclerosis trials plan to enrol fewer than 100 people.
Median target enrolment is 67 among the 20 trials that report a genuine target (sentinel values excluded). 12 of those (60%) plan for fewer than 100 participants.
-
Focal Segmental Glomerulosclerosis research is mostly interventional.
17 interventional and 3 observational studies make up this index (85% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
NEPTUNE Match Study
University of Michigan
NCT04571658
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
University of Michigan
NCT05650619
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Boehringer Ingelheim
NCT07220083
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Sanofi
NCT06500702
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Travere Therapeutics
NCT05003986
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Akebia Therapeutics
NCT07268638
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
Kaneka Medical America
NCT04065438
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Kaneka Medical America
NCT02235857
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)
NCT06664814
AMPK-activation by Metformin in FSGS: AMP-FSGS
Yale University
NCT06090227
taVNS for FRNS in Children
Northwell Health
NCT05588063
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Travere Therapeutics
NCT07219121
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
Northwell Health
NCT05583942
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
Beth Israel Deaconess Medical Center
NCT02194582
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Travere Therapeutics
NCT03493685
Atrasentan in Patients With Proteinuric Glomerular Diseases
Novartis Pharmaceuticals
NCT04573920
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
Travere Therapeutics
NCT05200871
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
Biogen
NCT03366337
Permeability Factor in Focal Segmental Glomerulosclerosis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00007475
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
Children's National Research Institute
NCT01113385
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 6 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Focal Segmental Glomerulosclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Focal Segmental Glomerulosclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Focal Segmental Glomerulosclerosis page
20 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Focal Segmental Glomerulosclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Travere Therapeutics sponsors the most Focal Segmental Glomerulosclerosis trials on record, review their full trial history before evaluating a specific study. See Travere Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Focal Segmental Glomerulosclerosis condition card totals 20 registered trials; most-linked intervention Sham device; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.